Atossa is focused on helping address significant unmet needs across the continuum of breast cancer.
1-in-8
1-in-8 women experience breast cancer.
2nd leading
2nd leading cause of cancer death in American women.
170,000
Around 170,000 women in the U.S are living with metastatic breast cancer.
20 to 30%
About 20% to 30% of women with early-stage cancer later develop metastatic breast cancer.
(Z)-endoxifen – Our Answer
(Z)-endoxifen is a powerful selective estrogen receptor modulator (SERM) that has been developed to be nearly 100 times more potent than other SERMs, with a potentially improved tolerability profile.
(Z)-endoxifen has demonstrated broad utility across the entire breast cancer treatment paradigm, and Atossa is advancing (Z)-endoxifen to target multiple breast cancer settings, including metastatic breast cancer.
Learn about (Z)-endoxifen and our focus to advance its development for metastatic breast cancer and other high need breast cancer indications.